WAZZI-250 contains Azithromycin 250 mg, a macrolide antibiotic formulated for selected susceptible bacterial infections. A dependable PCD Pharma Antibiotic portfolio product.
Selected susceptible bacterial infections.
No.
Use only when prescribed and complete the course. Inform the physician about macrolide allergy, liver disease or heart-rhythm disorders. Avoid unnecessary antibiotic use.
Nausea, diarrhea, abdominal discomfort, vomiting and headache may occur. Rarely, liver injury or QT prolongation can occur.
WAZZI-250: Azithromycin binds to the bacterial 50S ribosomal subunit and inhibits bacterial protein synthesis, suppressing growth of susceptible organisms.
